Observation of Short-Term Effects of Rh-endostatin Combined with Chemotherapy for Medium and Advanced Nonsmall Cell Lung Cancer

Abstract

Objective To investigate and compare the short-term effect and safety of rh-endostatin(endostar) combined with chemotherapy and conventional chemotherapy for NSCLC.Methods One hundred and four 104 patients with advanced non-small cell lung cancer confirmed by histopathology or cytopathology,were divided into two groups.Forty-one patients were given rh-endostatin plus chemotherapy(trial group),and 63 patients were given chemotherapy only(control group).The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria and NCI CTC 3.0 respectively.Results Totally,data from the 104 patients were evaluable.The total response rate(RR) in two groups were 34.15% and 30.16%,and the total clinical benefit rate(CBR) were 73.17% and 71.43%,respectively.The RR of untreated patients was 34.78% and 39.02%,CBR was 73.91% and 80.49%.The RR of retreated patients was 33.33% and 13.64%,CBR was 72.22% and 54.55%.The RR of squamous cell carcinoma was 27.27% and 28.00%,CBR was 81.82% and 72.00%.The RR of adenocarcinoma was 36.67% and 31.58%,CBR was 70.00% and 71.05%.There was no significant difference in patients' quality of life in two groups,and the incidence rates of side effect showed no statistical difference between two groups(P0.05).Conclusion The chemotherapy combined with rh-endostatin tended to show a better efficacy than chemotherapy alone and was well-tolerated in patients with non-small cell lung cancer,especially for the retreated patients.